Summary of efficacy, impact on work productivity and activity, and safety of baricitinib in moderate-to-severe atopic dermatitis from two monotherapy phase III trials
Por:
Wollenberg, A, Carrascosa, JM, Lacour, JP, Reich, K, Eichenfield, L, Rubel, D, Cardillo, T, Gittens, B, Grond, S and Augustin, M
Publicada:
1 sep 2020
Resumen:
Filiaciones:
Wollenberg, A:
Ludwig Maximillian Univ, Munich, Germany
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias, Barcelona, Spain
Lacour, JP:
Ctr Hospitalouniv Nice, Nice, France
Reich, K:
Univ Med Ctr Hamburg Eppendorf, Translat Res Inflammatory Skin Dis, Hamburg, Germany
Eichenfield, L:
Univ Calif San Diego, San Diego, CA 92103 USA
Rady Childrens Hosp, San Diego, CA USA
Rubel, D:
Woden Dermatol, Canberra, ACT, Australia
Cardillo, T:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Gittens, B:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Grond, S:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Augustin, M:
Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
|